New York State Common Retirement Fund Acquires 47,567 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

New York State Common Retirement Fund increased its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 19.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 291,148 shares of the medical equipment provider's stock after purchasing an additional 47,567 shares during the period. New York State Common Retirement Fund owned approximately 0.07% of Smith & Nephew SNATS worth $8,260,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in Smith & Nephew SNATS by 4.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock valued at $224,000 after acquiring an additional 399 shares during the last quarter. Hexagon Capital Partners LLC increased its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the last quarter. National Bank of Canada FI increased its position in Smith & Nephew SNATS by 36.5% during the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 446 shares during the last quarter. GAMMA Investing LLC increased its position in Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock valued at $103,000 after acquiring an additional 666 shares during the last quarter. Finally, Marotta Asset Management boosted its stake in shares of Smith & Nephew SNATS by 6.4% during the first quarter. Marotta Asset Management now owns 12,613 shares of the medical equipment provider's stock valued at $393,000 after purchasing an additional 764 shares during the period. Institutional investors own 25.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group boosted their target price on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Smith & Nephew SNATS presently has a consensus rating of "Hold" and a consensus price target of $28.00.

Smith & Nephew SNATS Trading Up 0.9%

Shares of NYSE:SNN opened at $30.14 on Friday. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $31.72. The firm has a market capitalization of $13.20 billion, a price-to-earnings ratio of 13.95, a price-to-earnings-growth ratio of 0.92 and a beta of 0.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.89 and a quick ratio of 1.33. The business's 50 day moving average price is $29.48 and its 200-day moving average price is $27.66.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.